• Mashup Score: 4
    Wolters Kluwer Health - 3 year(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Source: lww.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of JRheumatology
      JRheumatology

      #Hydroxychloroquine -associated Hyperpigmentation in Chilblain #Lupus Erythematosus https://t.co/yMpH2gGZ9M #hcq #lupus #rheumatology #RheumTwitter #medtwitter https://t.co/SjdsqSPMSd

  • Mashup Score: 119
    Misguided Use of Hydroxychloroquine for COVID-19 - 3 year(s) ago

    This issue of JAMA contains yet another study, and certainly among the best published to date, demonstrating the lack of efficacy of hydroxychloroquine as a treatment of coronavirus disease 2019 (COVID-19).1 This study, from the National Heart, Lung, and Blood Institute PETAL Clinical Trials…

    Source: jamanetwork.com
    Categories: General Medicine Journals and Societies, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of JAMA_current
      JAMA_current

      The number of scientific articles that consistently & convincingly show the lack of efficacy of #HCQ as a highly hyped “cure” for #COVID19 represent the consequence of the irresponsible infusion of politics into the world of scientific evidence https://t.co/ULEQtvVYrD @msaagmd

  • Mashup Score: 0
    Risk of Hydroxychloroquine Retinopathy in the Community - ACR Meeting Abstracts - 4 year(s) ago

    Background/Purpose: Hydroxychloroquine (HCQ) is used in the treatment of a wide variety of autoimmune diseases. HCQ retinopathy is a feared complication of long-term use. The reported prevalence of this complication increased with the advent of optical coherence tomography (OCT) or visual field assessment (VFA), and is estimated to be approximately 7.5% after five years of […]

    Source: ACR Meeting Abstracts
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of DrAiLynTan
      DrAiLynTan

      #Hydroxychloroquine #retinopathy risk at 10 yrs lower compared to prevalence estimates 👉🏽https://t.co/vYSyYa3sKU by Dabit, @AliDuarteMD et al #ACR20 #0540 More evidence for low risk in recommended #HCQ dose in RA SLE @RheumJnl ➡️https://t.co/5Un43estoE ➡️https://t.co/rbwUXVJKOO https://t.co/hV0M98gObo

  • Mashup Score: 0
    ACR Convergence 2020 Spotlight - Day Three - Arthritis Research Canada - 4 year(s) ago

    Day 3 – Saturday, November 7 | 9 to 11 AM ET. Arthritis Research Canada, Research Scientist: Dr. HK Choi (UBC, Harvard), Poster Presentation. Title: Hydroxychloroquine Dose Reduction and SLE Flares. Guidelines for daily hydroxychloroquine (HCQ) dosages are lower than the traditional daily dosage for most lupus patients, but it is unknown whether lower dosages remain…

    Source: Arthritis Research Canada
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of Arthritis_ARC
      Arthritis_ARC

      Day 3 at #ACR20 Poster presentation. Study revealed patients with #lupus experienced more flares after reducing the dose of #HCQ to be compliant with new guidelines. @Arthritis_ARC Research Scientist, Dr. Hyon Choi. Learn more: https://t.co/GwPxbJG4Zb https://t.co/cex4OFLIBb

  • Mashup Score: 0
    Hydroxychloroquine Use Was Not Associated with QTc Length in a Large Cohort of SLE and RA Patients - ACR Meeting Abstracts - 4 year(s) ago

    Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone therapy for systemic lupus erythematosus (SLE), and is used as monotherapy and combined with other DMARDs in rheumatoid arthritis (RA). However, its use in the treatment of COVID-19 has raised concerns for the possibility of QTc prolongation and development of arrhythmia.  We therefore assessed QTc length in a large […]

    Source: ACR Meeting Abstracts
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of DrAiLynTan
      DrAiLynTan

      #Hydroxychloroquine not associated with prolonged QTc length in SLE & RA 👉🏽https://t.co/i9CfJDnLcM By Dr Park #ACR20 #0431 Also by @thedrugdoc et al @RheumJnl ➡️#HCQ-induced QT-prolongation not major safety issue at recommended doses in #rheumatology 👉🏽https://t.co/8aiBGF22Fx https://t.co/NhrhGhZvXn

  • Mashup Score: 0
    Investigational Treatments of Coronavirus Disease 2019 in Children - 4 year(s) ago

    This pharmacokinetic simulation study estimates appropriate pediatric-specific dosing regimens for hydroxychloroquine and remdesivir in the treatment of pediatric patients with COVID-19.

    Source: jamanetwork.com
    Categories: Latest Headlines, Pediatrics
    Tweet Tweets with this article
    • Profile photo of JAMAPediatrics
      JAMAPediatrics

      New @PediatricTrials study uses modeling and simulation to determine #pediatric dosing for potential #COVID19 drugs #hydroxychloroquine and #remdesivir; results show #HCQ concentrations are below those needed for an #antiviral effect https://t.co/C9wSAq4LHO

Load More